We aim to transform the lives of patients around the world, during every chapter of their transplant journey.
Olivier Charmeil
Executive Vice President, General Medicines
A Long Heritage in Transplant
More than 40 years of translating the promise of our medicines into new hope for transplant patients worldwide.1
Our portfolio of transplant medicines has been specifically developed to meet the needs of a broad range of patients and includes innovative, first-in-class therapies that are already a standard of care in many countries.2
We never settle. As a trusted partner, we are continuing to harness our expertise to address patient needs and transform the future of transplant care.
Nadin Al Shukor, Associate Scientist, Ghent, BelgiumLife-Saving Medical Advances
Since the first organ transplantation of a kidney in 1954, hundreds of thousands of transplants are successfully conducted every year. This triumph owes much to the medicines that help prevent or treat transplant rejection or post-transplant complications. We’re proud to have played our part for over 40 years, helping to bring life-changing moments to patients.
Did You Know?
Transplantation can lead to complications including transplant rejection and graft vs host disease (GVHD) which can be acute (aGVHD) or chronic (cGVHD).
10-20%
of kidney transplant patients face organ rejection.3
32%
of patients who receive a lung transplant survive only 10 years, with a median survival of 5.8 years. 4,5
Up to 50%
of patients who receive a donated stem cell transplant develop cGVHD. 6
Decades of innovation have made transplantation a life-saving medical advancement, however unmet medical needs remain for many patients.
Without effective treatments, transplanted organs can trigger immune disorders causing…
Debilitating physical symptoms and psychological distress that can significantly impact quality of life. 7,8,9
Increased risk of transplant failure or even death. 10
Significant long-term socioeconomic burden on healthcare systems and society. 7
Pedro Pittella, People Director, Sao Paulo, BrazilA Successful Transplant Is Only Half the Patient Journey
People often think that the process of organ or stem cell transplantation ends once the patient receives the transplant.
However, post-transplant care can cause many challenges impacting patient outcomes and quality of life.
Only by working together can we expand pre- and post-transplant treatment options and ensure timely patient access, so that no transplant patient is left behind.
Maâli Mnsari, Data Scientist and Camal Kettami, Medical Visit Director, Gentilly, FranceUnlocking Our Full Potential
Being a committed partner means going beyond providing therapies for patients. By leveraging our heritage and collaborating with the community, we strive to support transplant recipients at every step of their journey.
Raising awareness and driving education is critical to transforming outcomes. To aid this, we support the GVHD Alliance which provides helpful resources for those affected by GVHD and mark GVHD day every year on February 17th.
Al Hassan Casse, Scientist, France The Challenge Ahead
We’re taking on the complex challenges of transforming patient outcomes in both stem cell transplantation and solid organ transplantation while hoping to improve both life expectancy and quality of life for patients.
Our pipeline medicines have been designed to advance scientific understanding and address unmet needs across several transplant-related conditions bringing hope to more patients through treatment advances in the future.
We never settle. We continue to chase the miracles of science and leverage our scale, expertise, and pipeline along with our partners in the scientific and patient community to provide hope for even more patients undergoing transplant surgery.
References
- Mohty M, Bacigalupo A, et al. New Directions for Rabbit Antithymocyte Globulin (Thymoglobulin®) in Solid Organ Transplants, Stem Cell Transplants and Autoimmunity. Drugs. 2014; 74(14):1605–1634.
- U.S Food & Drug Administration. Advancing Health Through Innovation: New Drug Therapy Approvals 2021. Available at:Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (fda.gov). Last accessed: September 2024.
- Clayton, PA., McDonald, SP., et al. Long-Term Outcomes after Acute Rejection in Kidney Transplant Recipients: An ANZDATA Analysis. J Am Soc Nephrol. 2019;30(9):1697-1707
- Sun, H., Deng, M., et al. Graft dysfunction and rejection of lung transplant, a review on diagnosis and management. Clin Respir J. 2022; 16( 1): 5- 12.
- Yusen RD, Edwards LB, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. J Heart Lung Transplant 2016;35:1170-84. 10.1016/j.healun.2016.09.001
- Lee SJ, Onstad L, Chow EJ, et al. Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica. 2018; 103(9): 1535-1541
- Fiuza-Luces C, Simpson RJ, Ramirez M, et al. Physical function and quality of life in patients with chronic graft-versus-host-disease: A summary of preclinical and clinical studies and a call for exercise intervention trials in patients. Bone Marrow Transplant. 2016; 51(1): 13-26
- Kurosawa S, Oshima K et al. Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017; 23(10): 1749-1758
- Kurosawa S, Oshima K et al. Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017; 23(10): 1749-1758
- DeFilipp, Z., Alousi, A. M., et al. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. Blood advances. 2011;5(20), 4278–4284.